1. Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression
   Minehiko Inomata et al, 2024, Molecular and Clinical Oncology CrossRef